E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients ≥18 years with cancer in need of subcutaneous venous port will be offered to participate in the trial. The aim of the trial is to determine if patient-controlled sedation (PCS) with propofol and alfentanil reduces pain perception during implantation of subcutaneous venous port (SVP) in cancer patients. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients ≥18 years with cancer in need of subcutaneous venous port will be offered to participate in the trial. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In this multicenter RCT we aim to examine the effect of PCS with propofol and alfentanil on patients´ self-reported pain perception scores, overall satisfaction scores, sedation scores and incidence of adverse events.
The primary objective is to determine the efficacy of patient-controlled sedation (PCS) as adjunct to local anaesthesia (LA) on patients´ self-reported pain perception during SVP-implantation. Patients in the treatment arm will undergo SVP-insertion in LA combined with PCS and in the control arm SVP-insertion will be conducted in LA. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are analysis of patient distress and satisfaction as well as secondary efficacy outcomes and determination of the relative safety of the treatment arm on defined safety outcomes and all adverse events and costs. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria: • Adult patients (≥18 years) with cancer scheduled for SVP-implantation at participating anaesthesia departments.
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria: • Inability to operate the PCS apparatus, • Inability to communicate in Scandinavian languages. • Patients who require general anaesthesia or patients eligible for LA only on anesthesiologist´s assessment (i.e. severe sleep apnea). • Propofol or alfentanil allergy. • Non-fasting according to guidelines of the Swedish Society for Anaesthesia and Intensive Care (SFAI). • Failure to achieve peripheral vascular access. • Pregnancy • Previous participation in study All exclusion criteria as per implantation team´s assessment.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: The primary endpoint is assessment of patient-reported pain perception. Endpoints are assessed by the use of the numeric rating scale (NRS): • Maximal intraprocedural pain level on NRS
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary end point will be evaluated after the patient has received his /her subcutaneous venous port befor discharge home from the postoperative unit. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints: • satisfaction with pain treatment during implantation • maximal distress level • importance of receiving sedatives during implantation • overall satisfaction • overall satisfaction with the staff • maximal pain from arm with PCS infusion • importance of being in control of sedation administration • grading of implantation conditions by the implanting physician • perioperative and procedural time consumption • delivered doses of alfentanil and propofol • rescue-therapy by nurse • differences in cost
Safety endpoints: • arterial puncture • pneumothorax • hypotension • arrhythmia • hypoxia • airway intervention • respiratory rate
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The secondary end points will be evaluted pre-, intra- and postprocedurally. Evaluation will begin when the patient arrives to the preoperative unit and will end with discharge from the postoperative unit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
the comparator will be standard procedure without analgosedation |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |